ANI Pharmaceuticals
ANIP
190 hedge funds and large institutions have $664M invested in ANI Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 71 increasing their positions, 64 reducing their positions, and 23 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 64
4.29% more ownership
Funds ownership: 71.23% → 75.52% (+4.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less funds holding
Funds holding: 196 → 190 (-6)
6% less capital invested
Capital invested by funds: $704M → $664M (-$39.8M)
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
26% less call options, than puts
Call options by funds: $4.7M | Put options by funds: $6.33M
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$13.4M |
| 2 |
BlackRock
New York
|
+$8.14M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$7.22M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$7.22M |
| 5 |
Man Group
London,
United Kingdom
|
+$6.36M |
Top Sellers
| 1 |
MCM
Matarin Capital Management
New York
|
-$8.39M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$4.1M |
| 3 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$3.87M |
| 4 |
First Manhattan
New York
|
-$3.1M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$2.95M |
ANIP Hedge Fund Activity: Q3 2019 in Review
190 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q3 2019, worth a combined $664M — down 5.7% from $704M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ANIP and 18 opened new positions — a net loss of 5 holders — while 64 trimmed existing stakes and 71 added.
The largest buyer was Goldman Sachs, adding an estimated $13.4M. The largest seller was Matarin Capital Management, cutting an estimated $8.39M.
- 190 institutional investors held ANI Pharmaceuticals (ANIP) as of Q3 2019, down from 196 in Q2 2019.
- Funds reported $664M of ANI Pharmaceuticals stock for Q3 2019, down 5.7% quarter-over-quarter.
- 18 funds opened new ANI Pharmaceuticals positions in Q3 2019 and 23 closed out, a net change of -5 holders.
- The largest ANI Pharmaceuticals buyer in Q3 2019 was Goldman Sachs, an estimated $13.4M added.
- The largest ANI Pharmaceuticals seller in Q3 2019 was Matarin Capital Management, an estimated $8.39M sold.
Based on aggregated 13F filings for Q3 2019.